Literature DB >> 3897768

Hepatic and peripheral insulin resistance following streptozotocin-induced insulin deficiency in the dog.

S Bevilacqua, E J Barrett, D Smith, D C Simonson, M Olsson, P Bratusch-Marrain, E Ferrannini, R A DeFronzo.   

Abstract

Insulin resistance and insulin deficiency are both present in many patients with diabetes mellitus. We tested the hypothesis that insulin resistance can evolve from a primary lesion of the beta-cell secretory function. Insulin-mediated glucose uptake (insulin clamp), endogenous glucose production, and glucose-stimulated insulin secretion (hyperglycemic clamp) were measured in awake dogs before and four to six weeks after streptozotocin-induced diabetes mellitus. Streptozotocin (30 mg/kg) resulted in a significant rise in the mean fasting plasma glucose concentration from 104 +/- 2 mg/100 mL to 200 +/- 34 mg/100 mL, (P less than 0.05), and a slight decrease in the mean fasting plasma insulin concentration (from 21 +/- 2 microU/mL to 15 +/- 2 microU/mL). Under conditions of steady-state hyperglycemia (+75 mg/100 mL hyperglycemic clamp, insulin secretion was reduced by 75% in the streptozotocin-treated dogs (P less than 0.025), and the total amount of glucose metabolized decreased from 13.56 +/- 1.04 to 4.74 +/- 0.70 mg/min X kg (P less than 0.001). In the postabsorptive state, endogenous glucose production was slightly, although not significantly, higher in the diabetic dogs (3.05 +/- 0.46 v 2.51 +/- 0.22 mg/min . kg), while the glucose clearance rate was 35% lower (P less than 0.001). When the plasma insulin concentration was increased to approximately 45 microU/mL (insulin clamp) while holding plasma glucose constant at the respective fasting levels (99 +/- 1 and 186 +/- 30 mg/100 mL), endogenous glucose production was completely suppressed in control dogs but suppressed by only 51% (1.46 +/- 0.37 mg/min . kg, P less than 0.025) in diabetic animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3897768     DOI: 10.1016/0026-0495(85)90105-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle.

Authors:  L Rossetti; M R Lauglin
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

2.  Excessive glucose production, rather than insulin resistance, accounts for hyperglycaemia in recent-onset streptozotocin-diabetic rats.

Authors:  R Burcelin; M Eddouks; J Maury; J Kande; R Assan; J Girard
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

3.  Liver and muscle insulin sensitivity, glycogen concentration and glycogen synthase activity in a rat model of non-insulin-dependent diabetes.

Authors:  Y T Kruszynska; P D Home
Journal:  Diabetologia       Date:  1988-05       Impact factor: 10.122

4.  Novel canine models of obese prediabetes and mild type 2 diabetes.

Authors:  Viorica Ionut; Huiwen Liu; Vahe Mooradian; Ana Valeria B Castro; Morvarid Kabir; Darko Stefanovski; Dan Zheng; Erlinda L Kirkman; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-20       Impact factor: 4.310

5.  The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats.

Authors:  G Lisato; I Cusin; A Tiengo; S Del Prato; B Jeanrenaud
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

6.  The effect of prolonged hyperglycemia on metabolic alterations in the subtotally pancreatectomized rat.

Authors:  Y Noguchi; R N Younes; K C Conlon; N A Vydelingum; A Matsumoto; M F Brennan
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.

Authors:  L Rossetti; D Smith; G I Shulman; D Papachristou; R A DeFronzo
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

8.  Gosha-jinki-gan (a Herbal Complex) Corrects Abnormal Insulin Signaling.

Authors:  Bolin Qin; Masaru Nagasaki; Ming Ren; Gustavo Bajotto; Yoshiharu Oshida; Yuzo Sato
Journal:  Evid Based Complement Alternat Med       Date:  2004-07-21       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.